Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 13, 2003 - Issue 1
Submit an article Journal homepage
53
Views
9
CrossRef citations to date
0
Altmetric
Review

Proteasome inhibitors as therapeutic agents

Julian Adams Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA 02139, USA
Pages 45-57 | Published online: 02 Mar 2005

Bibliography

  • CLURMAN BE, SHEAFF RJ, THRESS K, GROUDINE M, ROBERTS JM: Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by CDK2 binding and cyclin phosphorylation. Genes Dev. (1996) 10(16):1979–1990.
  • BOUNPHENG MA, DIMAS JJ, DODDS SG, CHRISTY BA: Degradation of Id proteins by the ubiquitin-proteasome pathway. FASEB.I. (1999) 13(15):2257–2264.
  • DESAI SD, LIU LF, VAZQUEZ-ABAD D, DARPA P: Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumour drug camptothecin. Biol. Chem. (1997) 272(39):24159–24164.
  • MAKI CG, HUIBREGTSE JM, HOWLEY PM: In vivo ubiquitylation and proteasome-mediated degradation of p53(1). Cancer Res. (1996) 56:(11):2649–2654.
  • LI B, DOU QP: Box degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumour survival and progression. Proc. Nati Acad. Sci. USA (2000) 97(8):3850–3855.
  • KUMATORI A, TANAKA K, INAMURA N et al.: Abnormally high expression of proteasomes in human leukemic cells. Proc. Nati Acad. Sci. USA (1990) 87:(18):7071–7075.
  • LAVABRE-BERTRAND T, HENRY L, CARILLO S et al.: Plasma proteasome level is a potential marker in patients with solid tumours and hemopoietic malignancies. Cancer (2001) 92(10):2493–2500.
  • OWA T, YOSHINO H, YOSHIMATSU K, NAGASU T: Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents. Carr. Med. Chem. (2001) 8(12):1487–1503.
  • TEICHER BA, ARA G, HERBST R, PALOMBELLA VJ, ADAMS J: The proteasome inhibitor PS-341 in cancer therapy. Clin. Cancer Res. (1999) 5(9):2638–2645.
  • ADAMS J, PALOMBELLA VJ, SAUSVILLE EA et al.: Proteasome inhibitors: a novel class of potent and effective antitumour agents. Cancer Res. (1999) 59(11):2615–2622.
  • BOLD RJ, VIRUDACHALAM S, MCCONKEY DJ: Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. Surg. Res. (2001) 100(1):11–17.
  • BERENSON JR, MA HM, VESCIO R: The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma. Semin. Omni (2001) 28(6):626–633.
  • CUSACK JC Jr, LIU R, HOUSTON M et al: Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res. (2001) 61(9):3535–3540.
  • ••PS-341 prevented NF-x.13 activation incolon cancer cells following treatment with SN-38, leading to an enhanced apoptotic response to chemotherapy.
  • RUSSO SM, TEPPER JE, BALDWIN AS et al.: Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-icB. Int. j Radiat. Omni Biol. Phys. (2001) 50(1):183–193.
  • PERVAN M, PAJONK F, SUN JR, WITHERS HR, MCBRIDE WH: Molecular pathways that modify tumour radiation response. Am. Clin. Oncol (2001) 24(5):481–485.
  • RICHARDSON PG, BARLOGIE B, BERENSON J et al.: Phase II study of the proteasome inhibitor PS-341 in multiple myeloma patients (pts) with relapsed/ refractory disease: results from cohort 1 analysis. 38th Annual Meeting of the American Society of Clinical Oncology Orlando, FL (May 17–24, 2002). Proceedings of the American Socieo, of Clinical Oncology (2002) 21:11a.
  • HERSHKO A, CIECHANOVER A: The ubiquitin system. Anna. Rev Biochem. (1998) 67:425–479.
  • ROTH AF, DAVIS NG: Ubiquitylation of the PEST-like endocytosis signal of the yeast a-factor receptor. J. Biol. Chem. (2000) 275(11):8143–8153.
  • MARCHAL C, HAGUENAUER-TSAPIS R, URBAN-GRIMAL D: A PEST-like sequence mediates phosphorylation and efficient ubiquitylation of yeast uracil permease. Mol Cell Biol. (1998) 18(1):314–321.
  • CONAWAY RC, BROWER CS, CONAWAY JW: Emerging roles of ubiquitin in transcription regulation. Science (2002) 296(5571):1254–1258.
  • EYTAN E, GANOTH D, ARMON T, HERSHKO A: ATP-dependent incorporation of 20S protease into the 26S complex that degrades proteins conjugated to ubiquitin. Proc. Natl. Acad. Sci. USA (1989) 86(20):7751–7755.
  • BRANNIGAN JA, DODSON G, DUGGLEBY HJ et al: A protein catalytic framework with an N-terminal nucleophile is capable of self-activation. Nature (1995) 378(6555):416–419.
  • ROHRWILD M, COUX O, HUANG HC et al.: Hs1V-Hs1U: A novel ATP-dependent protease complex in Escherichia coli related to the eukaryotic proteasome. Proc. Natl. Acad. Sci. USA (1996) 93(12):5808–5813.
  • LUPAS A, KOSTER AJ, BAUMEISTER W: Structural features of 26S and 20S proteasomes. Enzyme Protein (1993) 47(4-6):252–273.
  • TOKUNAGA F, GOTO T, KOIDE T et al.: ATP- and antizyme-dependent endoproteolysis of ornithine decarboxylase to oligopeptides by the 26 S proteasome. .1 Biol. Chem. (1994) 269(26):17382–17385.
  • KISSELEV AF, GOLDBERG AL: Proteasome inhibitors: from research tools to drug candidates. Chem. Biol. (2001) 8(8):739–758.
  • WILKINSON KD: Ubiquitylation and deubiquitylation: targeting of proteins for degradation by the proteasome. Semin. Cell Dev. Biol. (2000) 11(3):141–148.
  • LARSEN CN, PRICE JS, WILKINSON KD: Substrate binding and catalysis by ubiquitin C-terminal hydrolases: identification of two active site residues. Biochemistry (1996) 35(21):6735–6744.
  • YANG Y, FANG S, JENSEN JP, WEISSMAN AM, ASHWELL JD: Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science (2000) 288:874–877.
  • CHADEBECH P, BRICHESE L, BALD IN V, VIDAL S, VALETTE A: Phosphorylation and proteasome-dependent degradation of Bc1-2 in mitotic-arrested cells after microtubule damage. Biochem. Biophys. Res. Commun. (1999) 262:823–827.
  • ZHAO J, TENEV T, MARTINS LM, DOWNWARD J, LEMOINE NR: The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle- dependent manner.ScL (2000)113:4363–4371.
  • TATEBE H, YANAGIDA M: Cut8, essential for anaphase, controls localization of 26S proteasome, facilitating destruction of cyclin and Cut2. Can: Biol. (2000) 10:1329–1338.
  • PAGANO M, TAM SW, THEODORAS AM et al: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science (1995) 269:682–685.
  • CAYROL C, DUCOMMUN B: Interactionwith cyclin-dependent kinases and PCNA modulates proteasome-dependent degradation of p21. Oncogene (1998) 17:2437–2444.
  • NAWAZ Z, LONARD DM, DENNIS AP, SMITH CL, O'MALLEY BW: Proteasome-dependent degradation of the human estrogen receptor. Proc. Nati Acad. Sci. USA (1999) 96:1858–1862.
  • SEGNITZ B, GEHRING U: The functionof steroid hormone receptors is inhibited by the hsp90-specific compound geldanamycin. J. Biol. Chem. (1997) 272:18694–18701.
  • MASUYAMA H, MACDONALD PN: Proteasome-mediated degradation of the vitamin D receptor (VDR) and a putative role for SUG1 interaction with the AF-2 domain of VDR. I Cell. Biochem. (1998) 71:429–440.
  • SALVAT C, JARIEL-ENCONTRE I, ACQUAVIVA C, OMURA S, PIECHACZYK M: Differential directing of c-Fos and c-Jun proteins to the proteasome in serum-stimulated mouse embryo fibroblasts. Oncogene (1998) 17:327–337.
  • NESBIT CE, TERSAK JM, PROCHOWNIK EV: MYC oncogenes and human neoplastic disease. Oncogene (1999) 18:3004–3016.
  • PAL OMBELLA VJ, RANDO OJ, GOLDBERG AL, MANIATIS T: The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell (1994) 78:773–785.
  • BOYER SN, WAZER DE, BAND V: E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. (1996) 56:4620–4624.
  • ADAMS J, BEHNKE M, CHEN S et al: Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg. Med. Chem. Lett. (1998) 8(4):333–338.
  • LEE DH, GOLDBERG AL: Selective inhibitors of the proteasome-dependent and vacuolar pathways of protein degradation in Saccharomyces cerevisiae. Biol. Chem. (1996) 271(4027280–27284.
  • SHAH SA, POTTER MW, CALLERY MP: Ubiquitin proteasome pathway: implications and advances in cancer therapy. Surg. Oncol (2001) 10:(1-2):43–52.
  • DICK LR, CRUIKSHANK AA, GRENIER L et al: Mechanistic studies on the inactivation of the proteasome by lactacystin: a central role for clasto-lactacystin beta-lactone. J. Biol. Chem. (1996) 271(13):7273–7276.
  • FENTEANY G, STANDAERT RF, LANE WS et al: Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science (1995) 268(5211):726–731.
  • KOZLOWSKI L, STOKLOSA T, OMURA S et al.: Lactacystin inhibits cathepsin A activity in melanoma cell lines. Tumour Biol. (2001) 22(4):211–215.
  • ELLIOTT PJ, PIEN CS, MCCORMACK TA, CHAPMAN ID, ADAMS J: Proteasome inhibition: A novel mechanism to combat asthma. Allergy Clin. Immunol (1999) 104(2 Pt 1):294–300.
  • CAMPBELL B, ADAMS J, SHIN YK, LEFER AM: Cardioprotective effects of a novel proteasome inhibitor following ischaemia and reperfusion in the isolated perfused rat heart. J. Ma Cell Cardiol (1999) 31(2):467–476.
  • MENG L, MOHAN R, KWOK BH et al: Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo anti-inflammatory activity. Proc. Natl. Acad. Sci. USA (1999) 96:(18)10403–10408.
  • MENG L, KWOK BH, SIN N, CREWS CM: Eponemycin exerts its antitumour effect through the inhibition of proteasome function. Cancer Res. (1999) 59(12):2798–2801.
  • MYUNG J, KIM KB, CREWS CM: The ubiquitin-proteasome pathway and proteasome inhibitors. Med. Res. Rev (2001) 21(4):245–273.
  • KOHNO J, KOGUCHI Y, NISHIO M et al.: Structures of TMC-95A-D: novel proteasome inhibitors from Apiospora montagnei sacc. TC 1093. J. Org. Chem. (2000) 65(4):990–995.
  • ELOFSSON M, SPLITTGERBER U, MYUNG J, MOHAN R, CREWS CM: Towards subunit-specific proteasome inhibitors: synthesis and evaluation of peptide alpha',beta'-epoxyketones. Chem. Biol. (1999) 6(11):811–822.
  • NAM S, SMITH DM, DOU QP: Ester bond-containing tea polyphenols potently inhibit proteasome activity M vitro and in vivo. J. Biol. Chem. (2001) 276(16):13322–13330.
  • PAHL HL, KRAUSS B, SCHULZE-OSTHOFF K et al.: The immunosuppressive fungal metabolite gliotoxin specifically inhibits transcription factor NF-kappaB. Exp. Med. (1996) 183(01829–1840.
  • ORLOWSKI RZ, ESWARA JR, LAFOND-WALKER A et al.: Tumour growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res. (1998) 58(19):4342–4348.
  • •Early work showing that transformation with c-myc sensitised cells to apoptotic death after treatment with the proteasome inhibitor Z-LLF-CHO.
  • MASDEHORS P, MERLE-BERAL H, MAGDELENAT H, DELIC J: Ubiquitin-proteasome system and increased sensitivity of B-CLL lymphocytes to apoptotic death activation. Leak. Lymphoma (2000) 38(5-6):499–504.
  • DELIC J, MASDEHORS P, OMURA S et al.: The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo-and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-a-initiated apoptosis. Br. .1. Cancer (1998) 77(7):1103–1107.
  • MASDEHORS P, MERLE-BERAL H, MALOUM K et al.: Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes. Blood (2000) 96(1):269–274.
  • MITSIADES CS, TREON SP, MITSIADES N et al.: TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood (2001) 98(3):795–804.
  • HIDESHIMA T, RICHARDSON P, CHAUHAN D et al.: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis and overcomes drug resistance in human multiple myeloma cells. Cancer Res. (2001) 61(7):3071–3076.
  • DREXLER HC: Activation of the cell deathprogramme by inhibition of proteasome function. Proc. Natl. Acad. Sci. USA (1997) 94(3):855–860.
  • DREXLER HC, RISAU W, KONERDING MA: Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEB (2000) 14(1):65–77.
  • SIU WY, AROOZ T, POON RY: Differential responses of proliferating versus quiescent cells to adriamycin. Exp. Cell Res. (1999) 250(1):131–141.
  • FRANKEL A, MANS, ELLIOTT P, ADAMS J, KERBEL RS: Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Gin. Cancer Res. (2000) 6(9):3719–3728.
  • SOLIGO D, SERVIDA F, DELIA D et al.: The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI. Br. .1. Haematol (2001) 113(1):126–135.
  • OYAIZU H, ADACHI Y, OKUMURA T et al: Proteasome inhibitor 1 enhances paclitaxel-induced apoptosis in human lung adenocarcinoma cell line. Oncol Rep. (2001) 8(4):825–829.
  • KURLAND JF, MEYN RE: Protease inhibitors restore radiation-induced apoptosis to Bc1-2- expressing lymphoma cells. Int. J. Cancer (2001) 96(6):327–333.
  • ••Preclinical rationale for PS-341 treatmentin refractory multiple myeloma.
  • MA MH, PARKER KM, MANYAK Set al.: Proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma cells to chemotherapeutic agents and overcomes chemoresistance through inhibition of the NF-icB pathway. 43rd Annual Meeting of the American Society of Hematology Orlando, FL (Dec 7–11, 2001). Blood (2001) 98(11): 437a.
  • FEINMAN R, ARIS VM, VERGANO S et al.: Transcriptional gene expression profiles in drug-sensitive and Bc1-2-resistant myeloma cells in response to dexamethasone, arsenic trioxide and PS-341. 43rd Annual Meeting of the American Society of Hematology Orlando, FL (December 7–11, 2001). Blood (2001) 98(11): 368a.
  • AN B, GOLDFARB RH, SIMAN R, DOU QP: Novel dipeptidyl proteasome inhibitors overcome Bc1-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed but not normal, human fibroblasts. Cell Death Differ. (1998) 5(12):1062–1075.
  • •Thorough study of the aldehyde inhibitor CEP1612, including evidence for activity in a broad range of tumour types, bypass of Bc1-2 protection, and differential sensitivity of transformed cells over normal cells.
  • MARSHANSKY V, WANG X, BERTRAND R et al: Proteasomes modulate balance among proapoptotic and antiapoptotic Bc1-2 family members and compromise functioning of the electron transport chain in leukemic cells. Immunol (2001) 166(5):3130–3142.
  • DIETRICH C, BARTSCH T, SCHANZ F, OESCH F, WIESER RJ: p53 dependent cell cycle arrest induced by N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal in platelet-derived growth factor-stimulated human fibroblasts. Proc. Natl Acad. Sci. USA (1996) 93(20):10815–10819.
  • MACLAREN AP, CHAPMAN RS, WYLLIE AH, WATSON CJ: p53 dependent apoptosis induced by proteasome inhibition in mammary epithelial cells. Cell Death. DIME (2001) 8(3):210–218.
  • FAN XM, WONG BC, WANG WP et al.:Inhibition of proteasome function induced apoptosis in gastric cancer. Int. .1. Cancer (2001) 93:(4):481–488.
  • SHAH SA, POTTER MW, MCDADE TP et al.: 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. Cell Biochem. (2001) 82(1):110–122.
  • •Activity of PS-341 as a single agent and in combination with CPT-11 in pancreatic cancer.
  • CHEN C, EDELSTEIN LC, GELINAS C: The Rel/NF-icB family directly activates expression of the apoptosis inhibitor Bc1-x(L). MM. Cell Biol. (2000) 20(8):2687–2695.
  • WANG CY, MAYO MW, KORNELUK RG, GOEDDEL DV, BALDWIN AS Jr: NF-icB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c- IAP2 to suppress caspase-8 activation. Science (1998) 281:(5383):1680–1683.
  • BANCROFT CC, CHEN Z, DONG G et al.: Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves co-activation by MEK-MAPK and IKK- NF-icB signal pathways. Clin Cancer Res. (2001) 7:(2):435–442.
  • CHAUHAN D, UCHIYAMA H, AKBARALI Y et al: Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-icB. Blood (1996) 87(3):1104–1112.
  • MORI M, TERUI Y, TANAKA M et al.: Antitumour effect of I32-microglobulin in leukemic cell-bearing mice via apoptosis-inducing activity: activation of caspase-3 and nuclear factor-KB. Cancer Res. (2001) 61(11):4414–4417.
  • HUANG Y, JOHNSON KR, NORRIS JS, FAN W: Nuclear factor-icB/IicB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumour cells. Cancer Res. (2000) 60(16):4426–4432.
  • BOURS V, BONIZZI G, BENTIRES-ALJ M et al: NF-kappaB activation in response to toxical and therapeutical agents: role in inflammation and cancer treatment. Toxicology (2000) 153(1-3):27–38.
  • WANG CY, CUSACK JC Jr, LIU R, BALDWIN ASJ: Control of inducible chemoresistance: enhanced antitumour therapy through increased apoptosis by inhibition of NF-icB. Nat. Med. (1999) 5(4):412–417.
  • YANG J, RICHMOND A: Constitutive IicB kinase activity correlates with nuclear factor- lcB activation in human melanoma cells. Cancer Res. (2001) 61(12):4901–4909.
  • HUANG S, DEGUZMAN A, BUCANA CD, FIDLER IJ: Nuclear factor-kappaB activity correlates with growth, angiogenesis and metastasis of human melanoma cells in nude mice. Clin. Cancer Res. (2000) 6(6):2573–2581.
  • KORDES U, KRAPPMANN D, HEISSMEYER V, LUDWIG WD, SCHEIDEREIT C: Transcription factor NF-icB is constitutively activated in acute lymphoblastic leukaemia cells. Leukaemia (2000) 14(3):399–402.
  • UM JH, KANG CD, LEE BG et al: Increased and correlated nuclear factor-KB and Ku autoantigen activities are associated with development of multi-drug resistance. Oncogene (2001) 20(42):6048–6056.
  • THORNTON JD, LIU R, ORLOWSKI RZ et al.: Doxorubicin-induced NF-icB activation in breast cancer is overcome by proteasome inhibition, resulting in enhanced tumouricidal response to treatment. 87th Annual Clinical Congress of the American College of Surgeons New Orleans, LA (October 7–12, 2001). Proceedings of ACS (2001).
  • PAJONK F, PAJONK K, MCBRIDE WH: Inhibition of NF-icB, clonogenicity and radiosensitivity of human cancer cells.' Natl. Cancer Inst. (1999) 91(22):1956–1960.
  • SCHUTTE B, RAMAEKERS FC: Molecular switches that govern the balance between proliferation and apoptosis. Frog. Cell Cycle Res. (2000) 4:207–217.
  • JARPE MB, WIDMANN C, KNALL C et al.: Antiapoptotic versus pro-apoptotic signal transduction: checkpoints and stop signs along the road to death. Oncogene (1998) 17(11 Reviews):1475–1482.
  • ALMOND JB, SNOWDEN RT, HUNTER A et al: Proteasome inhibitor-induced apoptosis of B-chronic lymphocytic leukaemia cells involves cytochrome c release and caspase activation, accompanied by formation of an approximately 700 kDa Apaf-1 containing apoptosome complex. Leukaemia (2001) 15(9):1388–1397.
  • NAUJOKAT C, SEZER O, ZINKE H et al.: Proteasome inhibitors induced caspase-dependent apoptosis and accumulation of p21WAF1/Cipl in human immature leukemic cells. Euc Haematol (2000) 65(4):221–236.
  • WAGENKNECHT B, HERMISSON M, GROSCURTH P et al.: Proteasome inhibitor-induced apoptosis of glioma cells involves the processing of multiple caspases and cytochrome c release. Neurochem. (2000) 75(6):2288–2297.
  • LEBLANC R, CATLEY LP, HIDESHIMA T et al: Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. (2002) 62(17):4996–5000.
  • STEINER P, NEUMEIER H, LIGHTCAP ES et al: Generation of PS-341-adapted human multiple myeloma cells as experimental tools for analysis of proteasome function in cancer. 43rd Annual Meeting of the American Society of Hematology Orlando, FL (Dec 7–11, 2001). Blood(2001) 98(11): 310a.
  • •Resistance to PS-341 can be induced in vitro but is irrelevant to tumour response in mouse xenografts. In addition, PS-341 resistance was not conferred by overexpression of multi-drug resistance proteins.
  • SUNWOO JB, CHEN Z, DONG G et al: Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-KB, cell survival, tumour growth and angiogenesis in squamous cell carcinoma. Clin. Cancer Res. (2001) 7(5):1419–1428.
  • OHKAWA K, ASAKURA T, TAKADA K et al.: Calpain inhibitor causes accumulation of ubiquitinated P-glycoprotein at the cell surface: possible role of calpain in P-glycoprotein turnover. Int. Oncol. (1999) 15(4):677–686.
  • PALOMBELLA VJ, CONNER EM, FUSELER JW et al.: Role of the proteasome and NF-icB in streptococcal cell wall-induced polyarthritis. Proc. Natl Acad. ScL USA (1998) 95 (26) :15671–15676.
  • PHILLIPS JB, WILLIAMS AJ, ADAMS J, ELLIOTT PJ, TORTELLA FC: Proteasome inhibitor PS519 reduces infarction and attenuates leukocyte infiltration in a rat model of focal cerebral ischaemia. Stroke (2000) 31(7):1686–1693.
  • TAYLOR JP, HARDY J, FISCHBECK KH: Toxic proteins in neurodegenerative disease. Science (2002) 296(5575):1991–1995.
  • LAM YA, PICKART CM, ALBAN A et al: Inhibition of the ubiquitin-proteasome system in Alzheimer's disease. Proc. Natl. Acad. Sci. USA (2000) 97(18):9902–9906.
  • LAYFIELD R: Does an inhibition of the ubiquitin/26S proteasome pathway of protein degradation underlie the pathogenesis of non-familial Alzheimer's disease? Med. Hypotheses (2001) 56(3):395–399.
  • LAYFIELD R, ALBAN A, MAYER RJ, LOWE J: The ubiquitin protein catabolic disorders. Neuropathol. Appl. Neurobiol. (2001) 27(3):171–179.
  • BENCE NF, SAMPAT RM, KOPITO RR: Impairment of the ubiquitin-proteasome system by protein aggregation. Science (2001) 292:(5521):1552–1555.
  • BOSSOLA M, MUSCARITOLI M, COSTELLI P et al: Increased muscle ubiquitin mRNA levels in gastric cancer patients. Am. j Physiol. Regal. Integr. Comp Physiol. (2001) 280(5):R1518–R1523.
  • VOISIN L, BREUILLE D, COMBARET L et al.: Muscle wasting in a rat model of long-lasting sepsis results from the activation of lysosomal, Ca2+ -activated and ubiquitin-proteasome proteolytic pathways. J. Clin. Invest. (1996) 97(7):1610–1617.
  • MITCH WE, BAILEY JL, WANG X et al.: Evaluation of signals activating ubiquitin-proteasome proteolysis in a model of muscle wasting. Am.' Physiol (1999) 276(5 Pt 1):C1132–C1138.
  • PRICE SR, BAILEY JL, WANG X et al: Muscle wasting in insulinopenic rats results from activation of the ATP-dependent, ubiquitin-proteasome proteolytic pathway by a mechanism including gene transcription. Clin. Invest. (1996) 98(8):1703–1708.
  • WILLIAMS A, SUN X, FISCHER JE, HASSELGREN PO: The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer. Surgery(1999) 126(0744–749.
  • WATCHORN TM, WADDELL I, DOWIDAR N, ROSS JA: Proteolysis-inducing factor regulates hepatic gene expression via the transcription factors NF-(kappa)B and STAT3. FASEB.I. (2001) 15(3):562–564.
  • LIGHTCAP ES, MCCORMACK TA, PIEN CS et al.: Proteasome inhibition measurements: clinical application. Clin. Chem. (2000) 46(5):673–683.
  • NIX D, PIEN C, MADEN T et al.: Clinical development of a proteasome inhibitor, PS-341, for the treatment of cancer. 37th Annual Meeting of the American Society of Clinical OncologySan Francisco, CA (May 12–15, 2001). Proceedings of the American Society of Clinical Oncology (2001) 20:86a.
  • AGHAJANIAN C, SOIGNET S, DIZON DS et al: A Phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumour malignancies. Gin Cancer Res. (2002) 8(8):2505–2511.
  • ORLOWSKI RZ, STINCHCOMBE TE, MITCHELL BS et al.: Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. 1 Clin. Oncol. (2002) 20:(21).
  • CLARK JVV, RYAN D, DEES C et al.: Phase I dose-escalation study of the proteasome inhibitor, PS-341, plus irinotecan in patients with advanced solid tumours. Proceedings of the American Society of Clinical Oncology-38th Annual Meeting (2002) 21:93a.
  • RYAN DP, EDER JP, WINKLEMANN J et al.: Pharmacokinetic and pharmacodynamic Phase I study of PS-341 and gemcitabine in patients with advanced solid tumours. 38th Annual Meeting of the American Society of Clinical Oncology Orlando, FL (May 17–24, 2002). Proceedings of the American Society of Clinical Oncology (2002) 21:95a.
  • MEYER S, KOHLER NG, JOLY A: Cyclosporin A is an uncompetitive inhibitor of proteasome activity and prevents NF-icB activation. FEBS Lett. (1997) 413(2):354–358.
  • ANDRE P, GROETTRUP M, KLENERMAN P et al: An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation and T cell responses. Proc. Natl. Acad. Sci. USA (1998) 95:(22):13120–13124.
  • FIGUEIREDO-PEREIRA ME, CHEN WE, LI J, JOHDO O: The antitumour drug aclacinomycin A, which inhibits the degradation of ubiquitinated proteins, shows selectivity for the chymotrypsin-like activity of the bovine pituitary 20 S proteasome. Biol. Chem. (1996) 271(28):16455–16459.
  • RAO S, PORTER DC, HEN X et al.: Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl. Acad. Sci USA (1999) 96(14):7797–7802.
  • NUSSBAUM AK, DICK TP, KEILHOLZ W et al.: Cleavage motifs of the yeast 20S proteasome 13 subunits deduced from digests of enolase 1. Proc. Nati Acad. Sci. USA (1998) 95(21):12504–12509.

Websites

  • http://www.cancer.gov/cancer_information/ National Cancer Institute: Cancer information (2002).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.